

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

January 9, 2024

To Whom It May Concern:

Company: Topcon Corporation
Representative: President and CEO, Takashi Eto
(Code No.: 7732 TSE Prime Market)
Inquiry: Director & Senior Managing Executive Officer,
Haruhiko Akiyama
Accounting & Finance Division
(TEL: +81-3-3558-2532)

Notice Regarding Extraordinary Loss

Topcon Corporation (hereinafter referred to as “the Company”) hereby announces that the Company will post an extraordinary loss as a litigation related loss as follows in its consolidated financial results for the third quarter (from October 1 to December 31,2023) of the fiscal year ending March 31, 2024.

1. Regarding posting of extraordinary loss

Carl Zeiss Meditec, Inc. (hereinafter referred to as “Plaintiff”) filed a lawsuit against the U.S. subsidiaries of the Company, Topcon Medical Systems, Inc. and Topcon Healthcare Solutions, Inc. (hereinafter referred to as “U.S. subsidiaries”) insisting on that U.S. subsidiaries made use of the trade secrets of Plaintiff for their own business activities.

Though U.S. subsidiaries had been appropriately insisting that such fact did not exist, the Company had proceeded with negotiations toward a settlement by taking various circumstances such as the impact of prolonged litigation into account in a comprehensive way.

As a result, as settlement for the lawsuit was reached with Plaintiff on January 9, 2024, the Company will post an extraordinary loss as a litigation related loss in its consolidated financial results for the third quarter (from October 1 to December 31,2023) of the fiscal year ending March 31, 2024.

2. Future outlook

The Company will post 3,341 million yen of a litigation related loss which includes settlement fee on extraordinary loss. The amount of this extraordinary loss is a current estimate and the amount which will be actually presented on the consolidated statement of income shall be changed due to scrutiny of the costs etc.

Regarding the Impact of above matter on the financial forecast, since estimated amount of the impact of the matter was partially included in the financial forecast which was announced as “Notice regarding revision of financial forecasts” on October 27, 2023, there is no change of the financial forecast.